OurProducts

Prescription Cannabidiol (CBD)

EmpowerPharm is developing a prescription cannabidiol (CBD), designed to be consumed orally in a solid dose format. We source our CBD API from a Canadian supplier with a GMP facility approved by Health Canada.

SIGNIFICANT GLOBAL UNMET NEED IN SOCIAL ANXIETY DISORDER

  • Social anxiety disorder (SAD) is a mental health condition characterized by intense fear, anxiety, or embarrassment in social situations. Social anxiety treatment is a way of addressing this disorder and helping individuals to manage their symptoms.
  • SAD affects 15 million adults or 7.1% of the U.S. population. SAD is equally common among men and women and typically begins around age 13. According to an ADAA survey, 36% of people with social anxiety disorder report experiencing symptoms for 10 or more years before seeking help.
  • The Social Anxiety Treatment market was valued at USD $12B in 2022 and is projected to reach USD $16B by 2030, at a CAGR of 3.9% during the forecast period.
  • The Drug Medication and Devices segment was valued at USD $9B in 2022 and accounted for 60% of Social Anxiety Treatment Market in 2022. It is forecast to grow at a CAGR of 3.89% during 2023-2030 and it will be USD $10B in 2030.
  • Limited Innovation in 20 years

References:
Global Social Anxiety Treatment Market, Forecast to 2030 – Infinity Business Insights
NIMH: Social Anxiety Disorder.

 

THE POTENTIAL BLOCKBUSTER SOLUTION...
PRESCRIPTION CBD,

Developing the world’s first CBD prescription medication indicated for Social Anxiety Disorder.

Prescription drug to be approved in USA, Canada, and globally, allowing patients to be reimbursed by insurance companies and drug formularies​

High quality standardized dosages with enhanced bioavailability and IP protection

Manufactured under GMP Standards at our own
facility with a Drug Establishment Licence

Alternative anxiety treatment, not physically addictive as with benzodiazepines, and with fewer side effects than anti-depressants (SSRI/SNRI)*

References:
* https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4604171/